The PBS delisting of Panadol Osteo needs to be reconsidered in the light of cost and clinical safety implications, says Painaustralia. The organisation has highlighted the risk of adverse clinical events resulting from chronic pain sufferers switching from Panadol Osteo following its delisting with Health Minister Sussan Ley. In a letter to the Minister, Painaustralia
This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.